TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06216600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Participants will undergo ACT in combination with exercise and social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Participants will undergo ACT in combination with exercise and social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body weight circuit training
Description: Participants will learn and undergo body weight circuit training in combination with ACT and social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body weight circuit training
Description: Participants will learn and undergo body weight circuit training in combination with ACT and social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathetic social support
Description: Study participants will participate in empathetic social support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathetic social support
Description: Study participants will participate in empathetic social support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - list of resources
Description: A local list of resources to access exercise, therapy and social support will be provided.
Study: NCT06187064

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Van Clinic
Description: The investigators will implement a pilot clinic one evening per week, with the primary goal of measuring a community-based extension of SHE Clinic's impact on uptake and sustained use of HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD). The clinic will be dispatched with a driver, nurse, physician, and research assistant. The van clinic will be outfitted with space to obtain a confidential history and physical exam and include a space for sample collection. In addition to standard of care, the investigators will provide participants with rapid point-of-care HIV and STI testing, and HIV PrEP and MOUD counseling and prescriptions.
Study: NCT06326203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CELULAS TRONCO
Description: Cellular Therapy Treatment: The treatment will consist of \*\*20 participants (n=20) who will receive treatment with expanded mesenchymal stem cells (MSCs). The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive MSC application via perilesional injections and a biocovering produced by the study team, also containing the same cells (single session - the MSC-containing dressing will remain in contact with the ulcer for 7 days). After removal of the biological dressing, the ulcer will receive local care with a topical hydrogel dressing, dry gauze, and a crepe bandage, with a minimum of one change per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL DRESSING
Description: The control group will consist of 20 participants (n=20) who will receive local care for the ulcer. The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive the application of a conventional dressing with Hydrogel, dry gauze, and a crepe bandage. The patient will be instructed to change the dressing at least once a day.
Study: NCT05780359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: Sirolimus drug-eluting self-expanding stent available from 20mm to 250mm in length, 3.5mm to 7.5mm in diameter of superficial femoral and proximal popliteal arteries (SFA/PPA) cases for inhibiting in-stent restenosis and improve long-term outcome.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug coating balloon
Description: A proprietary lipophilic coating technology that uses magnesium sterate as excipient, facilitates paclitaxel transfer to the vessel wall, enhances drug delivery, and brings minimal downstream effect. Available from 20mm to 300 mm in length, 3mm to 12 mm in diameter, fits every SFA cases, reduces radiation exposure time.
Study: NCT05129358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: The subject is brought to mild dehydration (loss of approximately 1.5% of body weight) through intravenous injection of up to 40 ug Furosemide. The subject shall not ingest any fluid for the next 120 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rehydration
Description: The subject is rehydrated by oral intake of 1.5 liters Resorb Sport (Nestlé). The subject is monitored for 60 minutes following intake.
Study: NCT06044142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin and low laser therapy will be used on patients undergoing chemotherapy
Study: NCT04907877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic will be taken 1 time a day before breakfast for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken 1 time a day before breakfast for 28 days.
Study: NCT06146036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT snacks
Description: Cycling Exercise. 3 times per day 6 x 1 min at approximately 85-95% of HRmax

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint snacks
Description: Cycling Exercise. 3 times per day one ''all out'' sprint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No exercise, sedentary.
Study: NCT05090592

Intervention type: DEVICE
Intervention: orthokeratology
Description: orthokeratology wearing for myopia control
Study: NCT06375005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Telitacicept is fusion protein comprising a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the fragment crystallizable (Fc) domain of human immunoglobulin G (IgG). Telitacicept binds to and neutralizes the activity of two cell-signalling molecules, B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing the development and survival of plasma cells and mature B cells. Telitacicept will be subcutaneously injected at a dose of 160mg per week, lasting for 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: All patients will receive background therapy with Mycophenolate Mofetil (MMF), administered orally at a dose of 0.5g twice daily for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: All patients will receive background therapy with Mycophenolate Mofetil (MMF), administered orally at a dose of 0.5g twice daily for 48 weeks.
Study: NCT06197568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene Tartrate (AZU-101)
Description: 0.1 μg vaginal dose of AZU-101 weekly for 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene Tartrate (AZU-101)
Description: 0.5 μg vaginal dose of AZU-101 weekly for 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene Tartrate (AZU-101)
Description: 1 μg vaginal dose of AZU-101 weekly for 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene Tartrate (AZU-101)
Description: 0.1 μg vaginal dose of AZU-101 twice-weekly for 8 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene Tartrate (AZU-101)
Description: 0.5 μg vaginal dose of AZU-101 twice-weekly for 8 doses
Study: NCT05090592

Intervention type: DRUG
Intervention: 0.01 atropine
Description: 0.01% atropine eye drop prevent myopic progression
Study: NCT05242510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patching
Description: The subject will occlude the non-dominant eye for 24 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prism Adaptation
Description: The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
Study: NCT05098353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 25-75 mg per day for 6 weeks
Study: NCT04889820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: In this study, patients with obstructive colon cancer will be divided into two groups; in the control group, curative surgery will be performed within 2 weeks after successful SEMS placement, and in the experimental group, 3 cycles of neoadjuvant chemotherapy will be administered into patients who undergo successful SEMS placement and then curative surgery will be performed after neoadjuvnat chemotherapy. After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curative resection
Description: After successful SEMS placement, curate resection will be performed for all enrolled patients regardless of neoadjuvant chemotherapy.
Study: NCT06125847

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT006
Description: Single intravenous infusion of NGGT006 at dose 1 (7.5e12vg/kg), dose 2 (1.5e13vg/kg) , dose 3 (3e13vg/kg) and dose 4 (4e13vg/kg).
Study: NCT04889820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curative resection
Description: After successful SEMS placement, curate resection will be performed for all enrolled patients regardless of neoadjuvant chemotherapy.
Study: NCT05915455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCP-facing Portfolio Diet Infographic + Informative Video
Description: Resources to evaluate include the healthcare professional-facing Portfolio Diet infographic (1-page) and 4-minute accompanying video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Portfolio Diet Application
Description: Resource to evaluate includes the Portfolio Diet mobile application
Study: NCT05707806

Intervention type: DEVICE
Intervention: MRI
Description: Enables the use of custom pulse sequence
Study: NCT06382298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COTTONSEED OIL
Description: Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as cottonseed oil for 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MATCHED PUFA DIET
Description: Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs from oils with similar fatty acid composition as CSO for 28 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Participants are provided a breakfast shake that meets 20% of participant's daily estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
Study: NCT05677516

Intervention type: PROCEDURE
Intervention: ablation- pulmonary vain isolation- crioablation
Description: Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.

Intervention type: PROCEDURE
Intervention: ablation- pulmonary vain isolation- crioablation
Description: Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the cryoablation technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated using a cryoablation balloon. Cryoablation procedures are performed under local anesthesia. The procedure is performed using X-ray fluoroscopy.

Intervention type: PROCEDURE
Intervention: ablation- pulmonary vain isolation- pulsed field ablation (PFA)
Description: Pulmonary vein isolation is the electrical isolation of the pulmonary veins from the left atrium. It can be performed using the pulsed field ablation (PFA) technique. The procedure begins with venous access through the femoral vein through which catheters and electrodes are inserted. Then, the left atrium is accessed through a transseptal puncture and the pulmonary veins are isolated with a PFA electrode. PFA procedures are performed under general anesthesia. The procedure is performed using X-ray fluoroscopy.
Study: NCT05360771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SnowyTM PFO closure system
Description: Percutaneously occlusion of PFO with SnowyTM PFO closure system
Study: NCT04348123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Survey questionnaire seeks to collect data relevant to mammogram completion, barriers, and facilitators

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Session
Description: After the survey, clinic staff will conduct brief, culturally-appropriate educational session about breast health and mammography delivered by a female public health educator with experience in the underserved community. Educational session will explain screening options and address common barriers
Study: NCT05794204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMP-A03 - Dose 1
Description: Patients will randomized to low dose of RMP-A03

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMP-A03 - Dose 2
Description: Patients will be randomized to high dose of RMP-A03

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RMP-A03 Placebo
Description: Patients will be randomized to RMP-A03 Placebo
Study: NCT05141422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150 tablet、efavirenz
Description: SHR2150 tablet single dose, Efavirenz single dose.
Study: NCT05392465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial mobilization group
Description: Fascial mobilization+ conventional treatment (3 sessions per week). MFR is thought to work directly on restricted fascia; practitioners use knuckles or elbow to slowly sink into the fascia, and the pressure applied to contact the restricted fascia, apply tension, or stretch the fascia. MFR involves application of gentle stretch the pressure applied is a few grams of force, and the hands tend to follow the direction of fascial restriction, hold the stretch, and allow the fascia to release itself + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation).A total of 40-45 min session three times a week on alternate days for three weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physical therapy
Description: Conventional Therapy (3 sessions per week). In this treatment group conventional treatment for chronic neck pain will be given which includes hot pack, Neck Isometrics and Neck Stretches. Hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotators).A total of 40-45 min session three times a week on alternate days for three weeks On eligible participants baseline assessment was done,3 session were given per week.
Study: NCT05904067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID Convalescent Plasma
Description: 200 ml of COVID Convalescent Plasma at +14 days, +28 days, +2 months, and +3 months following hematopoietic stem cells transplantation.
Study: NCT05360017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: litestepper single lower limb rehabilitation training robot
Description: The experimental group adopts litestepper single lower limb rehabilitation training robot walking training on the basis of routine rehabilitation management of stroke patients with hemiplegia, walking training once a day, 40 ± 5 minutes each time; The control group was treated with routine rehabilitation management of stroke patients with hemiplegia. The trial was an open design. Both researchers and subjects knew the treatment allocation and conducted three evaluations within 21 days to evaluate the effectiveness and safety of litestepper single lower limb rehabilitation training robot in the training of lower limb motor function of stroke patients with hemiplegia.
Study: NCT05360771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardi-o-fix PFO occluder
Description: Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
Study: NCT06585644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib in combination with Anrotinib and chemotherapy
Description: The enrolled patients are planned to receive preoperative treatment with a combination of furmonertinib and anrotinib, along with platinum-based doublet chemotherapy. Three weeks after the completion of this treatment, they will undergo curative lung lobe resection and systemic lymph node dissection. Postoperatively, they will continue taking furmonertinib for one year. In case of disease progression, they will be switched to comprehensive therapy.
Study: NCT06388824

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients undergoing surgical abortion received a single injection of 5ml 0.9% normal saline after the beginning of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Patients undergoing surgical abortion received a single injection of 0.2mg/kg esketamine after the beginning of surgery
Study: NCT06253195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-43395
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered via intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered via intramuscular injection.
Study: NCT05908474

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Enriched fibre water
Description: Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enriched fibre water
Description: Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%\* of your recommended daily fibre intake and 100%\* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
Study: NCT05431673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 500mg/day for 4 weeks used as single or combination treatment for Rhinoscleroma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Rifampin 600mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
Study: NCT05965089

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AX-202
Description: Humanized monoclonal antibody
Study: NCT04704908

Intervention type: DRUG
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Description: The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant

Intervention type: DRUG
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Description: The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant

Intervention type: DRUG
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Description: The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant